Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

被引：3

作者：

Karimi, Leena ^{[1
]}

Alves, Carla L. ^{[1
]}

Terp, Mikkel G. ^{[1
]}

Tuttolomondo, Martina ^{[1
]}

Portman, Neil ^{[2
,3
]}

Ehmsen, Sidse ^{[1
,4
]}

Johansen, Lene E. ^{[1
]}

Bak, Martin ^{[5
]}

Lim, Elgene ^{[2
,3
]}

Ditzel, Henrik J. ^{[1
,6
,7
]}

机构：

[1] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense, Denmark

[2] Garvan Inst Med Res, Sydney, NSW, Australia

[3] Univ New South Wales Sydney, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia

[4] Odense Univ Hosp, Inst Clin Res, Dept Oncol, Odense, Denmark

[5] Sydvestjysk Sygehus, Dept Pathol, Esbjerg, Denmark

[6] Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark

[7] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, DK-5000 Odense, Denmark

来源：

CANCER COMMUNICATIONS | 2023年 / 43卷 / 06期

关键词：

PLUS FULVESTRANT; MONARCH; 2; ABEMACICLIB; ALPELISIB;

D O I：

10.1002/cac2.12425

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：720 / 725

页数：6

共 9 条

[1] Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer [J].

Alves, Carla L. ;

Ehmsen, Sidse ;

Terp, Mikkel G. ;

Portman, Neil ;

Tuttolomondo, Martina ;

Gammelgaard, Odd L. ;

Hundebol, Monique F. ;

Kaminska, Kamila ;

Johansen, Lene E. ;

Bak, Martin ;

Honeth, Gabriella ;

Bosch, Ana ;

Lim, Elgene ;

Ditzel, Henrik J. .

NATURE COMMUNICATIONS, 2021, 12 (01)

[2] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[3] PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer [J].

Costa, Carlotta ;

Wang, Ye ;

Ly, Amy ;

Hosono, Yasuyuki ;

Murchie, Ellen ;

Walmsley, Charlotte S. ;

Huynh, Tiffany ;

Healy, Christopher ;

Peterson, Rachel ;

Yanase, Shogo ;

Jakubik, Charles T. ;

Henderson, Laura E. ;

Damon, Leah J. ;

Timonina, Daria ;

Sanidas, Ioannis ;

Pinto, Christopher J. ;

Mino-Kenudson, Mari ;

Stone, James R. ;

Dyson, Nicholas J. ;

Ellisen, Leif W. ;

Bardia, Aditya ;

Ebi, Hiromichi ;

Benes, Cyril H. ;

Engelman, Jeffrey A. ;

Juric, Dejan .

CANCER DISCOVERY, 2020, 10 (01) :72-85

[4] Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines [J].

Hollestelle, Antoinette ;

Elstrodt, Fons ;

Nagel, Jord H. A. ;

Kallemeijn, Wouter W. ;

Schutte, Mieke .

MOLECULAR CANCER RESEARCH, 2007, 5 (02) :195-201

[5] Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer [J].

Jansen, Valerie M. ;

Bhola, Neil E. ;

Bauer, Joshua A. ;

Formisano, Luigi ;

Lee, Kyung-Min ;

Hutchinson, Katherine E. ;

Witkiewicz, Agnieszka K. ;

Moore, Preston D. ;

Estrada, Monica Valeria ;

Sanchez, Violeta ;

Ericsson, Paula G. ;

Sanders, Melinda E. ;

Pohlmann, Paula R. ;

Pishvaian, Michael J. ;

Riddle, David A. ;

Dugger, Teresa C. ;

Wei, Wenyi ;

Knudsen, Erik S. ;

Arteaga, Carlos L. .

CANCER RESEARCH, 2017, 77 (09) :2488-2499

[6] Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study [J].

Rugo, Hope S. ;

Lerebours, Florence ;

Ciruelos, Eva ;

Drullinsky, Pamela ;

Ruiz-Borrego, Manuel ;

Neven, Patrick ;

Park, Yeon Hee ;

Prat, Aleix ;

Bachelot, Thomas ;

Juric, Dejan ;

Turner, Nicholas ;

Sophos, Nickolas ;

Zarate, Juan Pablo ;

Arce, Christina ;

Shen, Yu-Ming ;

Turner, Stuart ;

Kanakamedala, Hemanth ;

Hsu, Wei-Chun ;

Chia, Stephen .

LANCET ONCOLOGY, 2021, 22 (04) :489-498

[7] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results. [J].

Rugo, Hope S. ;

Borrego, Manuel Ruiz ;

Chia, Stephen K. L. ;

Juric, Dejan ;

Turner, Nicholas C. ;

Drullinsky, Pamela ;

Lerebours, Florence ;

Bianchi, Giulia Valeria ;

Nienstedt, Carolyn C. ;

Ridolfi, Antonia ;

Thuerigen, Astrid ;

Ciruelos, Eva .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[8]

Sledge GW, 2019, ANN ONCOL, V30, P856

[9] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy [J].

Sledge, George W., Jr. ;

Toi, Masakazu ;

Neven, Patrick ;

Sohn, Joohyuk ;

Inoue, Kenichi ;

Pivot, Xavier ;

Burdaeva, Olga ;

Okera, Meena ;

Masuda, Norikazu ;

Kaufman, Peter A. ;

Koh, Han ;

Grischke, Eva-Maria ;

Frenzel, Martin ;

Lin, Yong ;

Barriga, Susana ;

Smith, Ian C. ;

Bourayou, Nawel ;

Llombart-Cussac, Antonio .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) :2875-+

← 1 →